Chardan Capital initiates coverage of Agenus with Buy rating, $40 price target
Chardan Capital initiated coverage of Agenus (AGEN) with a Buy rating and $40 price target, implying 454% upside from the Sep 17 close of $7.22. The firm highlights strong clinical data for Agenus's immunotherapy candidates, BOT and BAL, in treating MSS colorectal cancer, and the company's strategic focus on an unmet medical need.
How this was made
The 30-second read
Why it matters
Analyst initiation could attract new capital and increase volatility.
Market read
Analyst coverage adds fresh catalyst for AGEN, potentially influencing biotech sector sentiment.
What to watch
Potential regulatory hurdles and competition in MSS colorectal cancer.
Background
Agenus (NASDAQ: AGEN) focuses on immunotherapy for cancer, with BOT and BAL candidates in Phase 3 trials.
Ticker impact
Chardan Capital initiated coverage with a Buy rating and a $40 price target, implying 454% upside.
Potential short-term rally as investors adjust expectations.
New coverage often triggers price moves, especially with a large upside target.
Market effects
May lift sentiment for biotech and immunotherapy peers.
Limited to US biotech sector.
Minor, confined to niche oncology market.
Counterpoint
Target may be overly optimistic given early-stage data.
Key entities
- Research FirmChardan Capital
Initiated coverage with a Buy rating.
- CompanyAgenus Inc.
Biotech firm developing BOT+BAL immunotherapy.
